|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Second-line Therapy With Levofloxacin After Failure of Treatment to Eradicate Helicobacter pylori Infection: Time Trends in a Spanish Multicenter Study of 1000 Patients显示文摘 | Javier P. Gisbert ángeles Pérez-Aisa Fernando Bermejo Manuel Castro-Fernández Pedro Almela Jesús Barrio ángel Cosme Inés Modolell Felipe Bory Miguel Fernández-Bermejo Luis Rodrigo Jesús Ortu?o Pilar Sánchez-Pobre Sam Khorrami Alejandro Franco Albert Tomas | 2013 | Journal of Clinical Gastroenterology2013，，2： | 5 |
| 2 | Nonbismuth Quadruple (Concomitant) Therapy: Empirical and Tailored Efficacy versus Standard Triple Therapy for Clarithromycin‐Susceptible Helicobacter pylori and versus Sequential Therapy for Clarithromycin‐Resistant Strains显示文摘 | Javier Molina‐Infante Carmen Pazos‐Pacheco Gema Vinagre‐Rodriguez Belen Perez‐Gallardo Carmen Due?as‐Sadornil Moisés Hernandez‐Alonso Guadalupe Gonzalez‐Garcia Jose M. Mateos‐Rodriguez Miguel Fernandez‐Bermejo Javier P. Gisbert | 2012 | Helicobacter2012，，4： | 4 |
| 3 | Preclinical evaluation of azathioprine plus buthionine sulfoximine in the treatment of human hepatocarcinoma and colon carcinoma显示文摘AIM: To evaluate the efficacy and the safety of azathioprine (AZA) and buthionine sulfoximine (BSO) bylocalized application into HepG2 tumor in vivo.METHODS: Different hepatoma and colon carcinoma cell lines (HepG2, HuH7, Chang liver, LoVo, RKO, SW-48, SW-480) were grown in minimal essencial medium supplemented with 10% fetal bovine serum and 1% antibiotic/antimycotic solution and maintained in a humidified 37 ℃ incubator with 5% CO2. These cells were pretreated with BSO for 24 h and then with AZA for different times. We examined the effects of this combination on some proteins and on cellular death. We also studied the eff icacy and the safety of AZA (6 mg/kg per day) and BSO (90 mg/kg per day) in HepG2 tumor growth in vivo using athymic mice. We measured safety by serological markers such as aminotransferases and creatine kinase.RESULTS: The in vitro studies revealed a new mechanism of action for the AZA plus BSO combination in the cancer cells compared with other thiopurines (6-mercaptopurine, 6-methylmercaptopurine, 6-thioguanine and 6-methylthioguanine) in combination with BSO. The cytotoxic effect of AZA plus BSO in HepG2 cells resulted from necroptosis induction in a mitochondrial-dependent manner. From kinetic studies we suggest that glutathione (GSH) depletion stimulates c-Jun amino-terminal kinase and Bax translocation in HepG2 cells with subsequent deregulation of mitochondria (cytochrome c release, loss of membrane potential), and proteolysis activation leading to loss of membrane integrity, release of lactate dehydrogenase and DNA degradation. Some of this biochemical and cellular changes could be reversed by N-acetylcysteine (a GSH replenisher). In vivo studies showed that HepG2 tumor growth was inhibited when AZA was combined with BSO.CONCLUSION: Our studies suggest that a combination of AZA plus BSO could be useful for localizedtreatment of hepatocellular carcinoma as in the currently used transarterial chemoembolization method. | Borja Hernández-Breijo Jorge Monserrat Sara Ramírez-Rubio Eva P Cuevas Diana Vara Inés Díaz-Laviada M Dolores Fernández-Moreno Irene D Román Javier P Gisbert Luis G Guijarro | 2011 | World Journal of Gastroenterology2011，17，34： | 2 |
| 4 | N-acetyl-L-cysteine combined with mesalamine in the treatment of ulcerative colitis: Randomized,placebo-controlled pilot study显示文摘AIM: To evaluate the effectiveness and safety of oral N-acetyl-L-cysteine (NAC) co-administration with mesalamine in ulcerative colitis (UC) patients. METHODS: Thirty seven patients with mild to moderate UC were randomized to receive a four-wk course of oral mesalamine (2.4 g/d) plus N-acetyl-L-cysteine (0.8 g/d) (group A) or mesalamine plus placebo (group B). Patients were monitored using the Modified Truelove-Witts Severity Index (MTWSI). The primary endpoint was clinical remission (MTWSI ≤ 2) at 4 wk. Secondary endpoints were clinical response (defined as a reduction from baseline in the MTWSI of ≥ 2 points) and drug safety. The serum TNF-α, interleukin-6, interleukin-8 and MCP-1 were evaluated at baseline and at 4 wk of treatment. RESULTS: Analysis per-protocol criteria showed clinical remission rates of 63% and 50% after 4 wk treatment with mesalamine plus N-acetyl-L-cysteine (group A) and mesalamine plus placebo (group B) respectively (OR = 1.71; 95% CI: 0.46 to 6.36; P = 0.19; NNT = 7.7). Analysis of variance (ANOVA) of data indicated a significant reduction of MTWSI in group A (P = 0.046) with respect to basal condition without significant changes in the group B (P = 0.735) during treatment. Clinical responses were 66% (group A) vs 44% (group B) after 4 wk of treatment (OR = 2.5; 95% CI: 0.64 to 9.65; P = 0.11; NNT = 4.5). Clinical improvement in group A correlated with a decrease of IL-8 and MCP-1. Rates of adverse events did not differ significantly between both groups. CONCLUSION: In group A (oral NAC combined with mesalamine) contrarily to group B (mesalamine alone), the clinical improvement correlates with a decrease of chemokines such as MCP-1 and IL-8. NAC addition not produced any side effects. | Luis G Guijarro Jose Mate Javier P Gisbert Jose Luis Perez-Calle Ignacio Marín-Jimenez Encarna Arriaza Tomás Olleros Mario Delgado Maria S Castillejo David Prieto-Merino Venancio Gonzalez Lara Amado Salvador Pea | 2008 | World Journal of Gastroenterology2008，14，18： | 2 |
| 5 | Empirical res- cue therapy after ltelicobacter pylori treatment failure : A lO-year single-centre study of 500 patients 显示文摘 | GISBERT J P GISBERT J L MARCOS S | 2008 | Aliment Pharm Therap2008，27，4： | 1 |
| 6 | De novo design-hop(p)ing against hope显示文摘 | GISBERT S | 2013 | Drug Discov Today Technol2013，10，4： | 1 |
| 7 | Gibberellin homeostasis in tobacco is regulated by gibberellin metabolism genes with different gibberellin sensitivity显示文摘 | Gallego-Giraldo L Ubeda-Tomds S Gisbert C | 2008 | Plant Cell Physiol2008，49，5： | 1 |
| 8 | Helicobacter pyIo- ri eradication therapy is more effective in peptic ulcer than in non-ulcer dyspepsia显示文摘 | Gisbert JP Marcos S Gisbert JL | 2001 | Eur J Gastroenterol Hepatol2001，13，11： | 1 |
| 9 | The fate of heterotopically grafted neural precursor cells in the normal and dystrophic adult mouse retina显示文摘 | Susanne P Marius A Gisbert R Melitta S Udo B | 2001 | Invest Ophthalmol Vis Sci2001，42，13： | 1 |
| 10 | A protein linkage map of the ESAT-6 secretion system I(ESX-1 ) of Mycobacterium tuberculosis显示文摘 | Janka T Gisbert S Ute M L | 2009 | Microbiological Research2009，164，： | 1 |
| 11 | Percutaneous occlusion of femoral artery pseudoaneurysm by para-aneurysmal saline injection显示文摘 | Gisbert G Joseph L Andrej S | 2003 | Catheter- ization and Cardiovascular Interventions2003，58，4： | 1 |
| 12 | Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures显示文摘 | GISBERT JP GISBERT JL MARCOS S | 2006 | Aliment Pharmaeol Ther2006，24，10： | 1 |
| 13 | Disease severity in familial cases of IBD显示文摘 | M. Andreu L. Márquez E. Domènech J.P. Gisbert V. García I. Marín-Jiménez M. Pe?alva F. Gomollón X. Calvet O. Merino E. Garcia-Planella N. Vázquez-Romero M. Esteve P. Nos A. Gutiérrez I. Vera J.L. Cabriada M.D. Martín A. Ca?as-Ventura J. Panés | 2014 | Journal of Crohn’s and Colitis2014，，3： | 1 |
| 14 | Empirical Helicobacter pylori 'rescue' therapy after failure of two eradication treatments显示文摘 | GISBERT JP GISBERT JL MARCOS S et cd | 2004 | Dig Liver Dis2004，36，1： | 1 |
| 15 | Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single- centre study of 500 patients显示文摘 | Gisbert JP Gisbert JL Marcos S | 2008 | Aliment Pharmacol Ther2008，27，4： | 1 |
| 16 | Helicobaster pylori first - line treatment and rescue options in patients allergic to penicillin 显示文摘 | Gisbert JP Gzsbert JZ Marcos S | 2005 | Aliment Pharmacol Ther2005，22，： | 1 |
| 17 | Rabeperazole-based therapies in Helicobacter pylori eradication显示文摘 | Gisbert JP Khorrami S Calvet X | 2003 | Aliment Pharmacol Ther2003，17，6： | 1 |
| 18 | Empirical rescue therapy after Helicobacter pylori treatment failure: a 10 - year single - centre study of 500 patients 显示文摘 | Gisbert JP Gisbert JL Marcos S | 2008 | Aliment Pharmacol Ther2008，27，4： | 1 |
| 19 | Third-line rescue:hera-PY with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures显示文摘 | Gisbert JP Gisbert JL Marcos S | 2006 | Aliment Pharmacol Ther2006，24，： | 1 |
| 20 | Glycemia responses in white sturgeon after oral administration of graded doses of D-glucose显示文摘 | Gisbert E Sainz R D Hung S S O | 2003 | Aqua2003，224，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员